Top of this page
Skip navigation, go straight to the content

Our Science Our science- test
 

Our science

 

UCB's goal is to command a leading position in discovering and developing new therapies to treat patients suffering from severe diseases. With a promising pipeline, our focus is on neurological and immunological diseases to provide new treatments for specialists and their patients.

 

From Patient Value Strategy to action in R&D.

image description
image description

Two types of drug

New biological entities (NBEs)

NBEs may be defined as biological products such as proteins, peptides, antibodies, viruses and vaccines used to prevent or treat disease. Sometimes referred to as large molecule drugs. UCB specialises in developing antibody-based drugs, with a large molecular weight, which are most often administered by injection or infusion.

By connecting chemistry and biology in new ways, UCB is leveraging the potential of these two disciplines to advance new research.

image description
image description

New chemical entities (NCEs)



UCB develops two main kinds of medicine: new chemical entities (NCEs) and new biological entities (NBEs).

NCEs are chemically-derived, man-made and developed to treat a wide range of diseases. They are referred to as ‘small molecule drugs’ and often designed to be taken orally (as a pill).

What's in a name

A marketed drug may have up to four different types of name: a chemical name, a company name, a generic name, and a brand name.

  • The chemical name is based on the compound's chemical structure
  • When a new drug is in development, it is given a code to identify it within the company. For example, CDP870 is UCB's company code for Cimzia®
  • The generic name is commonly used to identify a drug during its useful clinical lifetime.
  • The company that patents a drug usually also creates its brand name, trade name or trademark. Drugs are often designated with a registered trademark, for example, Cimzia®, Briviact®, Vimpat®, Keppra®, Neupro®. A drug may have more than one brand name.
image description
image description
 

Innovation

Stronger together

We believe sharing knowledge and expertise is essential for the rapid growth of scientific understanding. And that bringing innovative therapies to patients requires intensive cooperation.

That’s why we have teamed up with other leading companies across the pharmaceutical industry.

We have also developed a strong global network of internationally renowned scientists and academics, who collaborate with us in our drug discovery activities.
We, in turn, are happy to share our own skills and experience with peers and with the academic world

image description

Seize IT:  epileptic seizure detection device

SeizeIT2 is a clinically accurate seizure detection system for people with epilepsy. This discrete wearable device monitors several biosignals to allow a more precise quantitative analysis of seizure activity, so that people with epilepsy can receive treatment optimised for their specific condition.

It is a proof-of-concept device enabling precise, objective logging of seizures for people with epilepsy. The first prototype of this wearable allows comfortable and unobtrusive seizure monitoring outside of a hospital setting.

 
 

Antibody programme

At UCB we are continually striving to improve our technologies to help us generate the best therapeutic antibodies for patients and the best antibody tools for researchers. Due to significant investment and expansion of our capabilities we are able to offer access to our highly efficient antibody discovery technology.

 

Read our latest press releases


Arthritis & Rheumatology Publishes the First Randomized
Placebo-Controlled Study Over 52 Weeks in Non-Radiographic
Axial Spondyloarthritis Showing Positive Results for CIMZIA® (certolizumab pegol)


March, 11 

New Data Affirms Strength of UCB
Immuno-Dermatology Portfolio





March, 1

UCB builds on its R&D footprint to form a
research satellite facility within King’s College London





February, 15